ApicHope Pharmaceutical Group Co Ltd. Stock Analysis 300723.SZ

Apichope Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sales of chemical medicine, traditional Chinese medicine products, and biological vaccines. The company is headquartered in Guangzhou, Guangdong and currently employs 1,397 full-time employees. The company went IPO on 2017-11-16. The firm mainly focuses on the fields of pediatrics drug and chronic disease drug, and its product categories cover chemical medicine (including raw materials and preparations), special Chinese patent medicine, biological vaccines and other fields. The Company’s paediatric drugs are used to treat common diseases, such as children's influenza, colds, infectious diseases, functional dyspepsia and others. The Company’s chronic disease drugs are used for treatment of cardiovascular and cerebrovascular diseases, kidney diseases, digestive system diseases, liver diseases and other diseases. The Company’s main products include Fuganlin oral liquid, clindamycin hydrochloride palmitate dispersible tablets and other products. The firm mainly conducts its business in the domestic market.